Autolus Therapeutics plc(AUTL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Autolus Therapeutics plc (AUTL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AUTL at 27.8/100 on a 32-signal composite quality model, placing it at rank #2,574 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Autolus Therapeutics plc reports quarterly revenue of $45.7M, net income of $-39.1M, free cash flow of $-26.0M. Top institutional holders of AUTL by reported 13-F value include MAK CAPITAL ONE, Blackstone, Syncona Portfolio Ltd, based on the most recent SEC filings. AUTL trades on the Nasdaq exchange and files with the SEC under CIK 1730463. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AUTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Autolus Therapeutics plc directly from SEC EDGAR.